[Form 4] Aspira Women's Health Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aspira Women's Health Inc. insider grant: Chief Financial Officer Brian Hungerford was granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $0.41 per share. The option was granted and deemed executed on 09/02/2025, is exercisable beginning that date, and expires on 09/02/2035. Following the grant, Hungerford directly beneficially owns 100,000 option shares. The filing explains that 25,000 shares vest on 09/02/2026 and the remainder vests in equal monthly installments over the subsequent 36 months. The form is signed 09/04/2025.

Positive

• CFO received a 100,000-share option grant, clearly disclosed with exercise price and vesting schedule
• Vesting schedule specified: 25,000 shares vest on 09/02/2026 and remaining shares vest monthly over the next 36 months
• Exercise price and term provided: $0.41 exercise price with expiration on 09/02/2035

Negative

• None.

Insights

Financial Analyst

TL;DR: CFO granted a 100,000-share option at $0.41, vesting over four years; routine executive compensation.

The grant is a standard equity compensation award providing long-term incentives tied to share price performance. The $0.41 exercise price and a ten-year term to 2035 are explicitly stated. Vesting begins one year after grant with 25,000 shares vesting on 09/02/2026 and the balance monthly over 36 months, which aligns executive retention with multi-year performance. The transaction increases the CFO's direct beneficial ownership of optioned shares to 100,000.

Corporate Governance Expert

TL;DR: This is a disclosure of a typical executive option award; materiality is limited to compensation and ownership reporting.

The Form 4 documents a non-derivative grant in the form of an employee stock option with clear vesting schedule and exercise terms. The filing names the reporting person as the company's Chief Financial Officer and provides the required timeline and signature. There is no additional information on performance conditions or acceleration clauses in the document; the disclosure is confined to the option terms and vesting timetable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hungerford Brian

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC.

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, TX 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.41	09/02/2025		A		100,000		(1)	09/02/2035	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. 25,000 shares will vest on September 2, 2026. The remaining shares will vest in equal monthly installments over the next 36 months.

	/s/ Brian Hungerford	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aspira Women's Health (AWH) disclose in this Form 4 filing?

The filing discloses that CFO Brian Hungerford was granted an employee stock option for 100,000 shares at an exercise price of $0.41, granted on 09/02/2025.

When do the granted options to Brian Hungerford vest and expire?

The filing states 25,000 shares vest on 09/02/2026 and the remainder vests in equal monthly installments over the following 36 months; the option expires on 09/02/2035.

How many shares does Brian Hungerford beneficially own after the reported transaction?

After the reported transaction, Brian Hungerford directly beneficially owns 100,000 optioned shares as shown in the Form 4.

What is the exercise price of the options reported on the Form 4?

The exercise (conversion) price disclosed for the employee stock option is $0.41 per share.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by /s/ Brian Hungerford on 09/04/2025 as indicated in the filing.